BioSpace News Archive

Fresh Tracks Therapeutics, Inc. announced that, after conducting an extensive potential strategic alternatives process and careful consideration of the outcomes of this, its Board of Directors has approved a plan of liquidation and dissolution of the Company.

Gestalt Diagnostics is proud to announce our latest release – an AI algorithm for use on one of the broadest trained environments for commercial or research use.

Envoy Medical® Corporation (“Envoy”), a hearing health company, today announced the proposed slate of seven directors to be voted on during the special meeting of stockholders to be held by its merger partner

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company”), announced today that, further to its press release dated September 6, 2023, Mr. Daniel Cohen will not be standing for re-election as a director

HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, announced the pricing of its public offering of 8,000,000 shares of its common stock at an initial price to the public of $12.50 per share.

Everest Medicines announced that the Center for Drug Evaluation of the China National Medical Products Administration has recommended Priority Review for cefepime-taniborbactam for the treatment of complicated urinary tract infections, including pyelonephritis, based on the criteria of “innovative drugs for the prevention and treatment of major infectious diseases and rare diseases that meet urgent clinical needs.”

ARS Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration issued a Complete Response Letter regarding its New Drug Application for neffy® in the treatment of Allergic Reactions, including anaphylaxis for adults and children ≥30 kg. ARS Pharma plans to submit a Formal Dispute Resolution Request to appeal the issuance of this CRL.

Impulse Dynamics plc announced new leadership appointments, including Jason Spees to Chief Executive Officer, Shlomi Nachman to Chairman of the Board, and John Liddicoat, M.D., as a member of the Board of Directors.

Kura Oncology, Inc. today announced its participation in the upcoming Cantor Global Healthcare Conference 2023 being held in New York. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 10:55 a.m. ET / 7:55 a.m. PT on September 26, 2023.

Prelude Corporation today announced it will be presenting data using DCISionRT to identify limitations in current clinicopathologic factors alone to predict radiation benefit in women with ductal carcinoma in situ (DCIS).